Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pierre Feugier

Showing results (21-30 of 164) with videos related to

Pageof 17
Sort By:
Oncotarget|June 9, 2016
Relapsed diffuse large B-cell lymphoma present different genomic profiles between early and late relapsesJulien Broséus, Gaili Chen, Sébastien Hergalant, et al.
Cancer|June 16, 2010
Efficacy and safety of the combination of rituximab, fludarabine, and mitoxantrone for rituximab-naive, recurrent/refractory follicular non-Hodgkin lymphoma with high tumor burden: a multicenter phase 2 trial by the Groupe d'Etude des Lymphomes de l'Adulte (GELA) and Groupe Ouest Est des Leucémies et Autres Maladies du Sang (GOELAMS)Franck Morschhauser, Nicolas Mounier, Catherine Sebban, et al.
JACC. Case Reports|November 12, 2021
Primary Epicardial Malt Lymphoma: A New Physiopathologic Entity Mimicking a Pericardial Compressive SyndromeDaniel Grandmougin, Mahmoud Cheikh Bouhlel, Emilie Lardenois, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 19, 2008
Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA studyCatherine Sebban, Pauline Brice, Richard Delarue, et al.
American Journal of Hematology|November 28, 2014
Bendamustine and rituximab combination in the management of chronic lymphocytic leukemia-associated autoimmune hemolytic anemia: a multicentric retrospective study of the French CLL intergroup (GCFLLC/MW and GOELAMS)Anne Quinquenel, Christophe Willekens, Jehan Dupuis, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 2013
Efficacy and toxicity of two schedules of bortezomib in patients with recurrent or refractory follicular lymphoma: a randomised phase II trial from the Groupe d'Etude des Lymphomes de l'Adulte (GELA)Vincent Ribrag, Hervé Tilly, Olivier Casasnovas, et al.
Blood|July 13, 2006
Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA)Catherine Sebban, Nicolas Mounier, Nicole Brousse, et al.
Journal of Crohn'S & Colitis|September 19, 2020
Characteristics of Lymphoma in Patients with Inflammatory Bowel Disease: A Systematic ReviewMarie Muller, Julien Broséus, Pierre Feugier, et al.
Annals of Hematology|July 5, 2014
Recommendations of the SFH (French Society of Haematology) for the diagnosis, treatment and follow-up of hairy cell leukaemiaEdouard Cornet, Alain Delmer, Pierre Feugier, et al.
Hematological Oncology|August 15, 2018
Serum albumin or body mass index: Which prognostic factor for survival in patients with acute myeloblastic leukaemia?Lauriane Filliatre-Clement, Julien Broseus, Marc Muller, et al.
Pageof 17

Showing results (21-30 of 164) with videos related to

Sort By:
Pageof 17
Oncotarget|June 9, 2016
Relapsed diffuse large B-cell lymphoma present different genomic profiles between early and late relapsesJulien Broséus, Gaili Chen, Sébastien Hergalant, et al.
Cancer|June 16, 2010
Efficacy and safety of the combination of rituximab, fludarabine, and mitoxantrone for rituximab-naive, recurrent/refractory follicular non-Hodgkin lymphoma with high tumor burden: a multicenter phase 2 trial by the Groupe d'Etude des Lymphomes de l'Adulte (GELA) and Groupe Ouest Est des Leucémies et Autres Maladies du Sang (GOELAMS)Franck Morschhauser, Nicolas Mounier, Catherine Sebban, et al.
JACC. Case Reports|November 12, 2021
Primary Epicardial Malt Lymphoma: A New Physiopathologic Entity Mimicking a Pericardial Compressive SyndromeDaniel Grandmougin, Mahmoud Cheikh Bouhlel, Emilie Lardenois, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 19, 2008
Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA studyCatherine Sebban, Pauline Brice, Richard Delarue, et al.
American Journal of Hematology|November 28, 2014
Bendamustine and rituximab combination in the management of chronic lymphocytic leukemia-associated autoimmune hemolytic anemia: a multicentric retrospective study of the French CLL intergroup (GCFLLC/MW and GOELAMS)Anne Quinquenel, Christophe Willekens, Jehan Dupuis, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 2013
Efficacy and toxicity of two schedules of bortezomib in patients with recurrent or refractory follicular lymphoma: a randomised phase II trial from the Groupe d'Etude des Lymphomes de l'Adulte (GELA)Vincent Ribrag, Hervé Tilly, Olivier Casasnovas, et al.
Blood|July 13, 2006
Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA)Catherine Sebban, Nicolas Mounier, Nicole Brousse, et al.
Journal of Crohn'S & Colitis|September 19, 2020
Characteristics of Lymphoma in Patients with Inflammatory Bowel Disease: A Systematic ReviewMarie Muller, Julien Broséus, Pierre Feugier, et al.
Annals of Hematology|July 5, 2014
Recommendations of the SFH (French Society of Haematology) for the diagnosis, treatment and follow-up of hairy cell leukaemiaEdouard Cornet, Alain Delmer, Pierre Feugier, et al.
Hematological Oncology|August 15, 2018
Serum albumin or body mass index: Which prognostic factor for survival in patients with acute myeloblastic leukaemia?Lauriane Filliatre-Clement, Julien Broseus, Marc Muller, et al.
Pageof 17